Shore Capital Reiterates House Stock Rating for Poolbeg Pharma (LON:POLB)

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reissued by research analysts at Shore Capital in a research report issued to clients and investors on Thursday,London Stock Exchange reports.

Poolbeg Pharma Stock Down 41.7 %

LON POLB traded down GBX 2.96 ($0.04) on Thursday, hitting GBX 4.14 ($0.05). The company’s stock had a trading volume of 36,072,488 shares, compared to its average volume of 1,611,117. The firm has a market cap of £20.69 million, a PE ratio of -413.80 and a beta of 2.11. The company’s 50-day moving average is GBX 7.66 and its 200 day moving average is GBX 10.08. Poolbeg Pharma has a 1-year low of GBX 4.13 ($0.05) and a 1-year high of GBX 15.77 ($0.20).

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.